DE792292T1 - Waisen-rezeptor - Google Patents

Waisen-rezeptor

Info

Publication number
DE792292T1
DE792292T1 DE0792292T DE96931047T DE792292T1 DE 792292 T1 DE792292 T1 DE 792292T1 DE 0792292 T DE0792292 T DE 0792292T DE 96931047 T DE96931047 T DE 96931047T DE 792292 T1 DE792292 T1 DE 792292T1
Authority
DE
Germany
Prior art keywords
receptor
amino acid
acid sequence
dna sequence
receptor according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0792292T
Other languages
English (en)
Inventor
Eva - Karolinska Institute Novum 141 86 Huddinge Enmark
Jan-Ake - Karolinska Institute Novum 141 86 Huddinge Gustafsson
George G.J. M.-Karolinska Institut Novum 141 86 Huddinge Kuiper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Pharma AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE792292(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karo Bio AB filed Critical Karo Bio AB
Publication of DE792292T1 publication Critical patent/DE792292T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (12)

DE/EP U 79Z [File:ANM\KA4501 A1.doc] Ansprüche, 28.0i.98 96931047.3, Kara Bio AB -A- Ansprüche
1. Rezeptor ERß, der die Aminosäuresequenz der Figuren 1, 13A oder 14A oder im wesentlichen die gleiche Aminosäuresequenz wie die in den Figuren 1, 13A oder 14A gezeigte Aminosäuresequenz oder eine diesen Sequenzen in der Funktion ähnliche Aminosäuresequenz aufweist.
2. Rezeptor nach Anspruch 1, der eine Aminosäuresequenz aufweist, die in mehr als 95% mit der in den Figuren 1, 13A oder 14A gezeigten Sequenz identisch ist.
3. Rezeptor nach Anspruch 1 oder 2, der von einer Ratten- oder menschlichen Zelle abstammt.
4. Rezeptor nach Anspruch 1, 2 oder 3, der ein Östrogenrezeptor ist.
0 5. DNA-Sequenz, die einen Rezeptor gemäß Anspruch 1, 2, 3 oder 4 codiert.
6. DNA-Sequenz nach Anspruch 5, in der die DNA-Sequenz die in den Figuren 1, 13B oder 14B vorgegebene oder eine DNA-Sequenz ist, die ein Protein oder ein Polypeptid, das die Funktionalität des ERß aufweist, codiert.
7. Verwendung eines Rezeptors nach Anspruch 1, 2, 3 oder 4 oder einer DNA-Sequenz nach Anspruch 5 oder 6 in einem Test, um die Moleküle zu bestimmen, die den ERß binden.
8. Verwendung eines Rezeptors nach Anspruch 1, 2, 3 oder 4 oder einer DNA-Sequenz nach Anspruch 5 oder 6 in einem Test, um Moleküle für die Verwendung bei der Behandlung von ERa- oder ERß-spezifischen Krankheiten oder Zuständen zu bestimmen.
Ut/tK U /bZ
[Rle:ANM\KA4501 A1.doc] Ansprüche, 28.01.98 96931047.3, Karo Bio AB
9. Verwendung eines Rezeptors nach Anspruch 1, 2, 3 oder 4 oder einer DNA-Sequenz nach Anspruch 5 oder 6 in einem Test, um Moleküle für die Verwendung bei der Behandlung von Prostata- oder Eierstock-Krebs, gutartiger Prostatahyperplasie, Krankheiten des zentralen Nervensystems, Osteoporose oder kardiovaskulären Krankheiten zu bestimmen.
10. Verfahren zum Entwerfen eines Arzneimittels, welches ein Vergleichen der Bindung einer Testverbindung an ERa
und an ERß umfaßt.
11. - hERß und funktioneile Äquivalente davon.
12. Verwendung eines Rezeptors nach Anspruch 1, 2, 3 oder 4 beim Testen der möglichen Ostrogenwxrkung oder anderer hormoneller Wirkungen einer Substanz.
DE0792292T 1995-09-08 1996-09-09 Waisen-rezeptor Pending DE792292T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (1)

Publication Number Publication Date
DE792292T1 true DE792292T1 (de) 1998-09-03

Family

ID=27451339

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69603827T Expired - Lifetime DE69603827T3 (de) 1995-09-08 1996-09-09 Östrogen-Rezeptor
DE0792292T Pending DE792292T1 (de) 1995-09-08 1996-09-09 Waisen-rezeptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69603827T Expired - Lifetime DE69603827T3 (de) 1995-09-08 1996-09-09 Östrogen-Rezeptor

Country Status (12)

Country Link
US (2) US5958710A (de)
EP (2) EP0935000A3 (de)
JP (4) JP3131649B2 (de)
KR (1) KR100263137B1 (de)
AT (1) ATE183516T1 (de)
AU (1) AU715528B2 (de)
CA (1) CA2201098C (de)
DE (2) DE69603827T3 (de)
DK (1) DK0792292T4 (de)
ES (1) ES2135249T5 (de)
GR (2) GR980300029T1 (de)
WO (1) WO1997009348A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (de) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, ein Steroid Hormon Rezeptor Homolog
EP0980386A2 (de) * 1997-06-10 2000-02-23 Karo Bio Ab Östrogen-rezeptor kristalle und liganden
US7157568B1 (en) * 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
EP1012177B1 (de) * 1997-09-08 2006-08-09 Merck & Co., Inc. Östrogenrezeptor
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
ATE255452T1 (de) * 1999-04-09 2003-12-15 Karobio Ab Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
EP1400810A3 (de) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogenrezeptoren und Knochenkrankheit
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
EA007382B1 (ru) 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003050133A1 (en) * 2001-12-07 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
ES2427626T3 (es) 2003-02-21 2013-10-31 Styron Europe Gmbh Procedimiento para homo- o copolimerización de olefinas conjugadas
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CA2518819A1 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2005012220A2 (en) 2003-07-28 2005-02-10 Smithkline Beecham Corporation Cycloalkylidene compounds as modulators of estrogen receptor
EP1709443A2 (de) * 2003-12-18 2006-10-11 Procognia, Ltd. Verfahren zur analyse eines glykomoleküls
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
CA2047752C (en) * 1989-03-17 2001-07-10 Ronald M. Evans Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
EP0935000A2 (de) 1999-08-11
US5958710A (en) 1999-09-28
WO1997009348A2 (en) 1997-03-13
EP0935000A3 (de) 1999-09-08
JPH11502417A (ja) 1999-03-02
DE69603827T2 (de) 2000-02-24
DK0792292T3 (da) 2000-02-07
JP2005204667A (ja) 2005-08-04
GR980300029T1 (en) 1998-04-30
US7132261B2 (en) 2006-11-07
ATE183516T1 (de) 1999-09-15
CA2201098C (en) 2001-03-27
US20030113803A1 (en) 2003-06-19
EP0792292B1 (de) 1999-08-18
JP2002010788A (ja) 2002-01-15
EP0792292A2 (de) 1997-09-03
ES2135249T3 (es) 1999-10-16
DE69603827T3 (de) 2009-11-05
CA2201098A1 (en) 1997-03-13
GR3031618T3 (en) 2000-01-31
ES2135249T5 (es) 2009-09-10
JP2005204666A (ja) 2005-08-04
DE69603827D1 (de) 1999-09-23
DK0792292T4 (da) 2009-07-20
JP3131649B2 (ja) 2001-02-05
WO1997009348A3 (en) 1997-04-24
KR100263137B1 (ko) 2000-08-01
AU6988096A (en) 1997-03-27
EP0792292B2 (de) 2009-04-15
AU715528B2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
DE792292T1 (de) Waisen-rezeptor
Ernfors et al. Expression of nerve growth factor receptor mRNA is developmentally regulated and increased after axotomy in rat spinal cord motoneurons
Eyre et al. Collagen cross-linking. Isolation of cross-linked peptides from collagen of chicken bone
EP0149468B1 (de) Biologisch wirksame Substanz mit hormonellen Eigenschaften, Verfahren zu ihrer Herstellung und Verwendung von Histonen für medizinische Zwecke
DE69734157T2 (de) Parathyroidhormon-verwandthe peptidanaloge
DE69006100T2 (de) Fibronektin-Derivate.
Weber et al. Collagen type distribution and macromolecular organization of connective tissue in different layers of human skin
Yehuda et al. Enhanced brain cell proliferation following early adrenalectomy in rats
Ohtani et al. Evaluation of aspartic acid racemization ratios in the human femur for age estimation
WO1999032620A9 (de) Insulin-like growth factor binding protein fragmente und ihre verwendung
Gianoulakis et al. Biosynthesis and characterization of adrenocorticotropic hormone, alpha-melanocyte-stimulating hormone, and an NH2-terminal fragment of the adrenocorticotropic hormone/beta-lipotropin precursor from rat pars intermedia.
Hainaut et al. Insulin and insulin-like-growth-factor-I (IGF-I) receptors in Xenopus laevis oocytes. Comparison with insulin receptors from liver and muscle
Orzi et al. Repeated electroconvulsive shock increases glial fibrillary acidic protein, ornithine decar☐ ylase, somatostatin and cholecystokinin immunoreactivities in the hippocampal formation of the rat
DE3780179T2 (de) Herstellung von menschlichem erythropoietin.
WO1997023611A2 (de) Nukleinsäuresequenzen von genen der high mobility group proteine sowie verwendungen derselben
DE10333406A1 (de) T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
Xie et al. IL-1 down-regulates platelet-derived growth factor-alpha receptor gene expression at the transcriptional level in human osteoblastic cells.
DE4038189A1 (de) Humanes, epididymis-spezifisches polypeptid und dessen verwendung zur therapie und diagnose maennlicher infertilitaet
DE19525784A1 (de) Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
Palmer et al. Measurement of the synthesis rates of collagens and total protein in rabbit muscle
Ratajczak et al. The interaction site for tamoxifen aziridine with the bovine estrogen receptor
EP0121912A1 (de) Radioimmunverfahren zur Bestimmung von Thymosin-beta-4
DE69827808T2 (de) Protease-ähnliches protein
DuBois et al. Increased content of glucocorticold receptors in mouse muscular dystrophy
Pal et al. Tubulin and glial fibrillary acidic protein gene expression in developing fetal human brain at midgestation